AU615495B2 - Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations - Google Patents

Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations Download PDF

Info

Publication number
AU615495B2
AU615495B2 AU25818/88A AU2581888A AU615495B2 AU 615495 B2 AU615495 B2 AU 615495B2 AU 25818/88 A AU25818/88 A AU 25818/88A AU 2581888 A AU2581888 A AU 2581888A AU 615495 B2 AU615495 B2 AU 615495B2
Authority
AU
Australia
Prior art keywords
formula
active substance
ramipril
stabilized
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU25818/88A
Other languages
English (en)
Other versions
AU2581888A (en
Inventor
Werner Fulberth
Richard Leeb
Manfred Radau
Willi Stammberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of AU2581888A publication Critical patent/AU2581888A/en
Application granted granted Critical
Publication of AU615495B2 publication Critical patent/AU615495B2/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Alteration of Name(s) in Register under S187 Assignors: HOECHST AKTIENGESELLSCHAFT
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
    • C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
    • C08G59/40—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the curing agents used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU25818/88A 1987-11-24 1988-11-23 Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations Expired AU615495B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873739690 DE3739690A1 (de) 1987-11-24 1987-11-24 Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
DE3739690 1987-11-24

Publications (2)

Publication Number Publication Date
AU2581888A AU2581888A (en) 1989-05-25
AU615495B2 true AU615495B2 (en) 1991-10-03

Family

ID=6341084

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25818/88A Expired AU615495B2 (en) 1987-11-24 1988-11-23 Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations

Country Status (21)

Country Link
US (2) US5151433A (enExample)
EP (1) EP0317878B1 (enExample)
JP (1) JPH0768140B2 (enExample)
KR (1) KR970004908B1 (enExample)
CN (1) CN1028962C (enExample)
AT (1) ATE74513T1 (enExample)
AU (1) AU615495B2 (enExample)
CA (1) CA1338344C (enExample)
DE (2) DE3739690A1 (enExample)
DK (1) DK168423B1 (enExample)
ES (1) ES2033400T3 (enExample)
FI (1) FI93693C (enExample)
GR (1) GR3004925T3 (enExample)
HU (1) HU202100B (enExample)
IE (1) IE61173B1 (enExample)
IL (1) IL88460A0 (enExample)
NO (1) NO176550C (enExample)
NZ (1) NZ227032A (enExample)
PH (1) PH27416A (enExample)
PT (1) PT89061B (enExample)
ZA (1) ZA888734B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
ATE206304T1 (de) * 1995-12-27 2001-10-15 Janssen Pharmaceutica Nv Bioadhesive feste arzneimittelform
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
HUP0203326A3 (en) * 1999-08-30 2003-04-28 Sanofi Aventis Deutschland Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
CA2357982A1 (en) * 2001-09-28 2003-03-28 Bernard Charles Sherman Solid compositions comprising ramipril
EP1467717A1 (en) * 2002-01-15 2004-10-20 Ranbaxy Laboratories Limited Stable pharmaceutical compositions comprising ace inhibitor(s)
US20060177498A1 (en) * 2003-01-22 2006-08-10 Ramaswami Bharatrajan Solid pharmaceutical composition comprising ramipril
GB0301471D0 (en) * 2003-01-22 2003-02-19 Biochemie Gmbh Organic compounds
CA2530788C (en) * 2003-06-26 2010-02-09 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
AU2003300692A1 (en) * 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2394660A (en) * 2003-12-17 2004-05-05 Niche Generics Ltd Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
US20060045911A1 (en) * 2004-08-27 2006-03-02 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical formulations
WO2006052968A2 (en) * 2004-11-05 2006-05-18 King Pharmaceuticals Research & Development, Inc. Stabilized ramipril compositions and methods of making
US20080096979A1 (en) * 2004-11-08 2008-04-24 Rubicon Research Pvt. Ltd. Aqueous Pharmaceutical Coating
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
KR100679166B1 (ko) 2005-10-04 2007-02-06 신풍제약주식회사 안정성이 증진된 약제학적 조성물 및 그의 제조방법
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
MX2008012248A (es) * 2006-03-28 2009-02-20 Gelesis Inc Uso de materiales polimericos con otras sustancias para rendimiento mejorado.
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
WO2007120930A2 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
WO2007142628A1 (en) * 2006-06-02 2007-12-13 Teva Pharmaceutical Industries Ltd. Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
US20070281000A1 (en) * 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
DE602006000402T8 (de) * 2006-06-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Stabile Zubereitung enthaltend eine feuchtigkeitsempfindliche aktive Substanz und Verfahren zur Herstellung der Zubereitung.
AU2007264414A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ACE inhibitors
AU2007291602B2 (en) * 2006-08-28 2012-09-06 Sanofi-Aventis Deutschland Gmbh Methods of lowering glucose levels
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
PL382311A1 (pl) * 2007-04-27 2008-11-10 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna o polepszonej stabilności zawierająca inhibitor acetylocholinoesterazy lub farmaceutycznie dopuszczalną jego sól oraz sposób jej wytwarzania
CN101980701A (zh) 2008-03-28 2011-02-23 菲尔若国际公司 用于预防心血管疾病的胶囊
WO2010030735A2 (en) * 2008-09-11 2010-03-18 Aethos Pharmaceuticals, Inc. Stabilized coating for pharmaceutical formulations
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
BR112014020184B1 (pt) 2012-02-17 2021-11-30 Egis Gyógyszergyár Zrt Preparação farmacêutica que contém anlodipina e ra-mipril
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
HUP1300496A2 (hu) 2013-08-16 2015-03-02 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Stabil kombinációs gyógyszerkészítmény
TWI668285B (zh) * 2015-12-31 2019-08-11 長興材料工業股份有限公司 可熱聚合之組合物、由此形成之組成液及其用途
EP3275432A1 (en) 2016-07-25 2018-01-31 H e x a l Aktiengesellschaft Dosage form with ace inhibitor
EP4106733A2 (en) 2020-02-10 2022-12-28 Adamed Pharma S.A. Stable ramipril composition and fixed dose composition comprising thereof
CN115068434B (zh) * 2022-08-03 2023-05-09 昆山龙灯瑞迪制药有限公司 一种雷米普利片的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4104085A (en) * 1984-04-13 1985-10-17 Macewans Machinery Ltd. Steam-heated beater
AU7064987A (en) * 1986-03-27 1987-10-01 Sanofi-Aventis Deutschland Gmbh Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfunctions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3565559A (en) * 1968-03-11 1971-02-23 Sumitomo Chemical Co Process for making microcapsules
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
DE3039073A1 (de) * 1980-10-16 1982-05-19 Röhm GmbH, 6100 Darmstadt Umhuelltes acetylsalicylsaeurepraeparat
EP0050800B2 (en) * 1980-10-23 1995-06-07 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
GB8616669D0 (en) * 1986-07-09 1986-08-13 Merk Sharpe & Dohme Ltd Pharmaceutical compositions
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
US4808413A (en) * 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4898732A (en) * 1988-05-04 1990-02-06 The Clinipad Corporation Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4104085A (en) * 1984-04-13 1985-10-17 Macewans Machinery Ltd. Steam-heated beater
AU7064987A (en) * 1986-03-27 1987-10-01 Sanofi-Aventis Deutschland Gmbh Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfunctions

Also Published As

Publication number Publication date
JPH0768140B2 (ja) 1995-07-26
PT89061A (pt) 1988-12-01
DE3739690A1 (de) 1989-06-08
DK168423B1 (da) 1994-03-28
NO885213L (no) 1989-05-25
NZ227032A (en) 1991-05-28
EP0317878A1 (de) 1989-05-31
ES2033400T3 (es) 1993-03-16
KR890007739A (ko) 1989-07-05
FI885398A0 (fi) 1988-11-22
CA1338344C (en) 1996-05-21
FI93693B (fi) 1995-02-15
AU2581888A (en) 1989-05-25
US5151433A (en) 1992-09-29
GR3004925T3 (enExample) 1993-04-28
HUT48455A (en) 1989-06-28
KR970004908B1 (ko) 1997-04-08
IL88460A0 (en) 1989-06-30
PT89061B (pt) 1993-03-31
IE61173B1 (en) 1994-10-05
NO176550B (no) 1995-01-16
PH27416A (en) 1993-06-21
EP0317878B1 (de) 1992-04-08
DE3869919D1 (de) 1992-05-14
HU202100B (en) 1991-02-28
ZA888734B (en) 1989-07-26
CN1042917A (zh) 1990-06-13
NO885213D0 (no) 1988-11-23
DK653688D0 (da) 1988-11-23
CN1028962C (zh) 1995-06-21
FI885398A7 (fi) 1989-05-25
ATE74513T1 (de) 1992-04-15
JPH01165596A (ja) 1989-06-29
IE883505L (en) 1989-05-24
DK653688A (da) 1989-05-25
US5442008A (en) 1995-08-15
NO176550C (no) 1995-04-26
FI93693C (fi) 1995-05-26

Similar Documents

Publication Publication Date Title
US5442008A (en) Stabilized polymer film coated compounds and stabilized formulations in compressed from using same
AU661075B2 (en) Stabilized Pharmeceutical Compositions of HMG-CoA Reductase Inhibitors
US5211958A (en) Pharmaceutical composition and process for its preparation
EP1027037B1 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
KR100348842B1 (ko) 염기성물질로안정화된약제학적조성물
HU196708B (en) Process for producing pharmaceutical composition comprising omeprazol and suitable for treating deseases of the digestive system
IE64659B1 (en) Pimobendan compositions
US8008349B2 (en) Stable pharmaceutical preparation comprising levothyroxine sodium, gelatin and fillers and which is free of organic solvent residues
US5364646A (en) Oral pharmaceutical forms of pimobendan
KR20210047234A (ko) 프로톤 펌프 저해제 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 및 이의 제조방법
IE65373B1 (en) A tablet and granulate containing mesna as active substance
EP0505180B1 (en) High-content ibuprofen lysinate pharmaceutical formulation
AU611740B2 (en) Pharmaceutical composition and process for its preparation
US20050064029A1 (en) Stable pharmaceutical composition
TR2023015500A1 (tr) Bri̇varasetam i̇çeren deği̇şti̇ri̇lmi̇ş salimli bi̇r tablet kompozi̇syonu
NZ270729A (en) Fluvastatin sodium in an alkaline carrier
HU215191B (hu) Eljárás Levodopa és Carbidopa hatóanyag-kombinációt tartalmazó, szabályozott hatóanyag-leadású, központi dopaminhiányos állapotok kezeléséhez alkalmas orális gyógyszerkészítmény előállítására
HK1069772A (en) Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl) dodecanoic acid

Legal Events

Date Code Title Description
PC Assignment registered

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER OWNER WAS: HOECHST AKTIENGESELLSCHAFT